CAJ | 학술논문

目的：观察匹多莫德联合槐杞黄颗粒及单用匹多莫德治疗儿童反复呼吸道感染的疗效及对机体免疫功能的影响。方法选取159例符合入组标准的反复呼吸道感染患儿，按随机数字表法分为联合治疗组、单项治疗组和对照组，每组各53例，对照组给予退热、祛痰、镇咳、抗感染等常规治疗，联合治疗组在对照组治疗的基础上给予匹多莫德联合槐杞黄颗粒，单项治疗组只给予匹多莫德颗粒，随访6个月，治疗结束后观察患儿症状改善情况，检测 T 细胞亚群比例和免疫球蛋白浓度，进行三组临床疗效评判，随访期间统计复发次数。结果联合治疗组显效率为76%，总有效率为91%；单项治疗组显效率为59%，总有效率为72%；对照组显效率为27%，总有效率为49%，联合治疗组与对照组显效率、总有效率比较差异有统计学意义（P﹤0.01）；单项治疗组与对照组显效率、总有效率比较差异有统计学意义（P﹤0.01）；联合治疗组与单项治疗组显效率、总有效率比较差异有统计学意义（P﹤0.05）。随访期间平均复发次数联合治疗组为（1.5±0.4）次，单项治疗组为（2.3±0.4）次，对照组为（6.0±1.0）次，组间比较差异有统计学意义（P﹤0.01）。组间的退热时间、咳嗽消失时间、扁桃体肿大消退时间、肺部啰音消失时间比较差异均有统计学意义（P﹤0.01）。联合治疗组、单项治疗组治疗后 T 细胞亚群（ CD3﹢、CD4﹢、CD8﹢）、免疫球蛋白（ IgA、IgG、IgM）均较治疗前明显升高，差异有统计学意义；对照组治疗前后 T 细胞亚群、免疫球蛋白差异无统计学意义。结论匹多莫德可有效增强机体抗感染能力，但匹多莫德联合槐杞黄颗粒可显著增强反复呼吸道感染患儿细胞免疫及体液免疫功能，并且能补患儿气阴两虚，能够缓解急性发作期的症状与体征，明显降低疾病的复发次数，值得临床推广使用。目的：觀察匹多莫德聯閤槐杞黃顆粒及單用匹多莫德治療兒童反複呼吸道感染的療效及對機體免疫功能的影響。方法選取159例符閤入組標準的反複呼吸道感染患兒，按隨機數字錶法分為聯閤治療組、單項治療組和對照組，每組各53例，對照組給予退熱、祛痰、鎮咳、抗感染等常規治療，聯閤治療組在對照組治療的基礎上給予匹多莫德聯閤槐杞黃顆粒，單項治療組隻給予匹多莫德顆粒，隨訪6箇月，治療結束後觀察患兒癥狀改善情況，檢測 T 細胞亞群比例和免疫毬蛋白濃度，進行三組臨床療效評判，隨訪期間統計複髮次數。結果聯閤治療組顯效率為76%，總有效率為91%；單項治療組顯效率為59%，總有效率為72%；對照組顯效率為27%，總有效率為49%，聯閤治療組與對照組顯效率、總有效率比較差異有統計學意義（P﹤0.01）；單項治療組與對照組顯效率、總有效率比較差異有統計學意義（P﹤0.01）；聯閤治療組與單項治療組顯效率、總有效率比較差異有統計學意義（P﹤0.05）。隨訪期間平均複髮次數聯閤治療組為（1.5±0.4）次，單項治療組為（2.3±0.4）次，對照組為（6.0±1.0）次，組間比較差異有統計學意義（P﹤0.01）。組間的退熱時間、咳嗽消失時間、扁桃體腫大消退時間、肺部啰音消失時間比較差異均有統計學意義（P﹤0.01）。聯閤治療組、單項治療組治療後 T 細胞亞群（ CD3﹢、CD4﹢、CD8﹢）、免疫毬蛋白（ IgA、IgG、IgM）均較治療前明顯升高，差異有統計學意義；對照組治療前後 T 細胞亞群、免疫毬蛋白差異無統計學意義。結論匹多莫德可有效增彊機體抗感染能力，但匹多莫德聯閤槐杞黃顆粒可顯著增彊反複呼吸道感染患兒細胞免疫及體液免疫功能，併且能補患兒氣陰兩虛，能夠緩解急性髮作期的癥狀與體徵，明顯降低疾病的複髮次數，值得臨床推廣使用。
목적：관찰필다막덕연합괴기황과립급단용필다막덕치료인동반복호흡도감염적료효급대궤체면역공능적영향。방법선취159례부합입조표준적반복호흡도감염환인，안수궤수자표법분위연합치료조、단항치료조화대조조，매조각53례，대조조급여퇴열、거담、진해、항감염등상규치료，연합치료조재대조조치료적기출상급여필다막덕연합괴기황과립，단항치료조지급여필다막덕과립，수방6개월，치료결속후관찰환인증상개선정황，검측 T 세포아군비례화면역구단백농도，진행삼조림상료효평판，수방기간통계복발차수。결과연합치료조현효솔위76%，총유효솔위91%；단항치료조현효솔위59%，총유효솔위72%；대조조현효솔위27%，총유효솔위49%，연합치료조여대조조현효솔、총유효솔비교차이유통계학의의（P﹤0.01）；단항치료조여대조조현효솔、총유효솔비교차이유통계학의의（P﹤0.01）；연합치료조여단항치료조현효솔、총유효솔비교차이유통계학의의（P﹤0.05）。수방기간평균복발차수연합치료조위（1.5±0.4）차，단항치료조위（2.3±0.4）차，대조조위（6.0±1.0）차，조간비교차이유통계학의의（P﹤0.01）。조간적퇴열시간、해수소실시간、편도체종대소퇴시간、폐부라음소실시간비교차이균유통계학의의（P﹤0.01）。연합치료조、단항치료조치료후 T 세포아군（ CD3﹢、CD4﹢、CD8﹢）、면역구단백（ IgA、IgG、IgM）균교치료전명현승고，차이유통계학의의；대조조치료전후 T 세포아군、면역구단백차이무통계학의의。결론필다막덕가유효증강궤체항감염능력，단필다막덕연합괴기황과립가현저증강반복호흡도감염환인세포면역급체액면역공능，병차능보환인기음량허，능구완해급성발작기적증상여체정，명현강저질병적복발차수，치득림상추엄사용。
Objective To observe the effect of pidotimod and combined with huaiqihuang( a tra-ditional Chinese medicine)on recurrent respiratory tract infections and its influence on immune function. Methods One hundred and fifty-nine children with recurrent respiratory tract infections met the inclu-sion criteria were randomly divided into observation group,pidotimod group and control group,with 53 cases in each group. The control group was given conventional treatment,while the observation group was given pidotimod and huaiqihuang on the basis of conventional treatment,the pidotimod group was given pidotemod on the basis of conventional treatment. After follow-up for 6 months,the symptoms were ob-served,the levels of T cells subsets and immunoglobulin were detected,the clinical efficacy was evalua-ted,and the recurrences times were counted. Results The remarkable efficiency of the observation group,pidotimod group and the control group was 76%,59% and 27%,the total efficiency was 91%, 72% and 49%,the recurrences frequency were(1. 5 ± 0. 4),(2. 3 ± 0. 4)and( 6. 0 ± 1. 0)times,re-spectively. There were significant differences between the groups(P﹤0. 01). The time of defervescence, the disappearing time of coughing and pulmonary signs,and the recovery time of tonsil enlargement a-mong the three groups were significantly different( P﹤0 . 01 ). T cell subsets( CD3﹢,CD4﹢,CD8﹢) and immunoglobulin( IgA,IgG,IgM)of the observation group and the pidotimod group after treatment were significantly higher than those before treatment. T cell subsets( CD3﹢,CD4﹢,CD8﹢),immuno-globulin( IgA,IgG,IgM)of the observation group and the pidotimod group after treatment was significant-ly higher than that of the control group;there were significant differences. But these indicators of the con-trol group were not changed significantly after treatment. Conclusions Pidotimod can effectively improve the anti-infection ability. The therapy of pidotimod combined with huaiqihuang can significantly enhance the cellular immunity and humoral immunity,assist to alleviate the symptoms and signs of acute exacerba-tion,and reduce the recurrence frequency,so is worthy of clinical use in the treatment of recurrent respiratory tract infections.